Alpha Tau Medical Ltd. (DRTS)

Market Cap	253.27M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	69.01M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,285
Open	3.62
Previous Close	3.69
Day's Range	3.60 - 3.74
52-Week Range	3.00 - 20.65
Beta	n/a
Analysts	Buy
Price Target	17.60 (+379.56%)
Earnings Date	Mar 27, 2023

About DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: DRTS

Analyst Forecast

According to 10 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price forecast is $17.6, which is an increase of 379.56% from the latest price.

Price Target

$17.6

(379.56% upside)

Analyst Consensus: Buy